Prostacyclin and prostanoid modifiers aid ischemic skin flap survival.

Abstract

Prostacyclin, the stable prostacyclin analogue carbacyclin, the thromboxane synthetase inhibitor UK-38,485, and the phosphodiesterase inhibitor dipyridamole were tested on rabbit epigastric free flaps for their ability to improve flap survival after a period of ischemia. Control flaps infused with a balanced salt solution had a 39.9% survival, whereas prostacyclin, carbacyclin, and dipyridamole significantly increased flap survival to 68.4% (P less than 0.05), 66.4% (P less than 0.05), and 66.9% (P less than 0.05), respectively. UK-38,485 improved survival slightly to 47.6% although not significantly. The improved flap survival correlated with the vasodilatory properties of the three successful agents whereas the antithrombotic properties of UK-38,485 were not sufficient, on their own, to increase flap survival.

• Authors: K R Knight, H Kawabata, S A Coe, J A Angus, B M O'Brien, K Sakai
• Journal: The Journal of surgical research (J Surg Res) Vol. 50 Issue 2 Pg. 119-23 (Feb 1991) ISSN: 0022-4804 [Print] United States
• PMID: 1990215 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Imidazoles
• Prostaglandins, Synthetic
• dazmegrel
• Dipyridamole
• carboprostacyclin
• Epoprostenol
• Thromboxane-A Synthase

Topics

• Animals
• Dipyridamole (pharmacology)
• Epoprostenol (analogs & derivatives, pharmacology)
• Graft Survival (drug effects)
• Imidazoles (therapeutic use)
• Ischemia
• Prostaglandins, Synthetic (pharmacology)
• Rabbits
• Skin (blood supply)
• Skin Transplantation (immunology, physiology)
• Surgical Flaps
• Thromboxane-A Synthase (antagonists & inhibitors)